Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

Remo PanaccioneJean-Frederic ColombelSimon P L TravisPeter BossuytFilip BaertTomáš VaňásekAhmet DanalıoğluGottfried NovacekAlessandro ArmuzziWalter ReinischScott J JohnsonMarric BuessingEzequiel NeimarkJoel PeterssonWan-Ju LeeGeert R D'Haens

Published in: Gut (2019)

NCT01235689; Results.

Keyphrases

rheumatoid arthritis
study protocol
blood brain barrier
clinical trial
phase ii
juvenile idiopathic arthritis
randomized controlled trial
systemic lupus erythematosus
replacement therapy